Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Poor social support and loneliness in chronic headache: Prevalence and effect modifiers

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Vestibular migraine: diagnostic criteria1

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Twenty-five years of triptans - a nationwide population study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The ability of tonabersat to relieve the symptoms of migraine attacks with or without aura was evaluated in a randomized, double-blind, placebo-controlled, multicentre, parallel-group study. Patients received 20 or 40 mg of tonabersat, or 50 mg of sumatriptan (positive control), or placebo at the onset of a moderate or severe attack. Headache intensity, relief and recurrence were recorded for 24 h after dosing. On the basis of primary or secondary efficacy measures, tonabersat did not provide a clinically or statistically significant advantage over placebo. Tonabersat generally was well tolerated and had no effect on vital signs, electrocardiogram recordings or laboratory values. The lack of efficacy may be a function of the slow absorption of tonabersat. As a consequence of slow absorption, daily administration of tonabersat as prophylaxis for migraine attacks is under investigation in ongoing studies.
Original languageEnglish
JournalCephalalgia : an international journal of headache
Volume29
Issue numberSuppl 2
Pages (from-to)7-16
Number of pages9
DOIs
Publication statusPublished - 2009

Bibliographical note

Keywords: Adult; Analgesics; Benzamides; Benzopyrans; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Safety; Serotonin Agonists; Sumatriptan; Treatment Outcome

ID: 172618